Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating the role of oncogenic H3.3K27M mutations in pediatric diffuse intrinsic pontine glioma

FY 2019-20

Summary
"Diffuse Intrinsic Pontine Glioma (DIPG) is a devastating disease and is the leading cause of pediatric brain-tumour related death. The median survival rate after diagnosis is less than 1 year, and there is a desperate need for new treatments to be developed. However, efforts to create new therapies are limited by the lack of animal models that develop DIPG tumours genetically similar to those found in humans. To date, our lab and others have discovered a mutation, H3K27M, which occurs in nearly 80% of DIPG tumours. However, its exact role in these tumours is unknown. We believe that this mutation plays a role in the initiating stages of tumour development. To test this, I will determine which neural cells are the most susceptible to becoming tumour cells, and at which stage during normal development are these cells most likely to begin forming tumours. To do this, I will use mice that have the H3K27M mutation, and I will extract cells from different areas of the brain at different stages of development and characterize them. Using this information, I will create mice with the H3K27M mutation in the cell type that is most susceptible to becoming tumour cells, and express this mutation at the stage of development that is most able to form tumours. These mice will also have mutations in other genes, TP53 and PDGFRA. Mutations in these genes have been shown to occur in human DIPG tumours, and therefore this will aid in creating tumours in mice that are genetically similar to humans. The successful completion of these experiments will result in an animal model of DIPG, that creates tumours that accurately represent the human disease. With this model, we can begin identifying and testing new therapies that could potential help treat this devastating disease."
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428970
Name
Lubanszky Evan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of oncogenic H3.3K27M mutations in pediatric diffuse intrinsic pontine glioma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Diffuse Intrinsic Pontine Glioma; H3k27m; Mouse Model; Oncohistone; Pediatric High-Grade Glioma; Tumour Initiation; Tumour Modeling
Abstract
"Diffuse Intrinsic Pontine Glioma (DIPG) is a devastating disease and is the leading cause of pediatric brain-tumour related death. The median survival rate after diagnosis is less than 1 year, and there is a desperate need for new treatments to be developed. However, efforts to create new therapies are limited by the lack of animal models that develop DIPG tumours genetically similar to those found in humans. To date, our lab and others have discovered a mutation, H3K27M, which occurs in nearly 80% of DIPG tumours. However, its exact role in these tumours is unknown. We believe that this mutation plays a role in the initiating stages of tumour development. To test this, I will determine which neural cells are the most susceptible to becoming tumour cells, and at which stage during normal development are these cells most likely to begin forming tumours. To do this, I will use mice that have the H3K27M mutation, and I will extract cells from different areas of the brain at different stages of development and characterize them. Using this information, I will create mice with the H3K27M mutation in the cell type that is most susceptible to becoming tumour cells, and express this mutation at the stage of development that is most able to form tumours. These mice will also have mutations in other genes, <em>TP53</em> and <em>PDGFRA. </em>Mutations in these genes have been shown to occur in human DIPG tumours, and therefore this will aid in creating tumours in mice that are genetically similar to humans. The successful completion of these experiments will result in an animal model of DIPG, that creates tumours that accurately represent the human disease. With this model, we can begin identifying and testing new therapies that could potential help treat this devastating disease."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lubanszky, Evan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~